Pharvaris N.V. (PHVS)
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Pharvaris N.V.
NASDAQ:PHVSHealthcare · Biotechnology
-0.15%$33.53
AH$34.68+3.43%vs close
Mkt Cap$2.35B
Float38.06M
O/S70.2M
Vol
$ Vol
RVOL
Inst Own91.8%
SI6.5%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$196.29M
Total Assets$336.79M
Free Cash Flow-$153.32M
Debt & Equity
Debt 0%
Equity 100%
Total Debt$868K
Total Equity$303.07M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in PHVS's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$336.79M
Liabilities$33.72M
Accounts Receivable$5.08M
Accounts Payable$5.71M
Inventory$0
PP&E (Net)$1.56M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | - | - | - | - | - | - | - | - |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $9K | $686 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | -$9K | -$686 | $0 |
| Gross Margin | - | - | - | - | - | - | - | - |
| Research and Development | $139.07M | $110.12M | $73.26M | $64.1M | $39.98M | $24.85M | $7.11M | $4.07M |
| Selling, General, and Administrative | $50.66M | $52.65M | $35.01M | $32.78M | $20.5M | $6.99M | $2.91M | $746K |
| Other | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $189.73M | $162.76M | $108.27M | $96.88M | $60.48M | $31.84M | $10.02M | $4.82M |
| Operating Income (EBIT) | -$189.73M | -$162.76M | -$108.27M | -$96.88M | -$60.48M | -$31.85M | -$10.02M | -$4.82M |
| Operating Margin | - | - | - | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $18K | $311K | $103K | $0 | $0 |
| Interest Income | $0 | $6.11M | $0 | $18 | $299 | $103 | $5 | $0 |
| Other Income (Expense) | -$4.34M | $14.85M | -$3.25M | $12.36M | $12.82M | -$1.35M | -$21K | -$425 |
| Income Before Tax (EBT) | -$194.07M | -$147.91M | -$111.53M | -$84.52M | -$47.66M | -$33.2M | -$10.04M | -$4.82M |
| Income Tax Expense | $2.22M | $2.04M | $1.17M | $759K | $78K | -$106K | $0 | $425 |
| Net Income | -$196.29M | -$149.95M | -$112.7M | -$85.28M | -$47.74M | -$33.09M | -$10.04M | -$4.82M |
| Net Income Margin | - | - | - | - | - | - | - | - |
| Supplementary Data | ||||||||
| EPS | -2.97 | -2.48 | -2.63 | -2.27 | -1.41 | -0.85 | -0.25 | -0.14 |
| Diluted EPS | -2.97 | -2.48 | -2.63 | -2.27 | -1.41 | -0.85 | -0.25 | -0.14 |
| Weighted Average OS | 59.16M | 54.02M | 38.39M | 33.59M | 30.41M | 30.52M | 31.84M | 31.84M |
| EBITDA | -$193.6M | -$162.46M | -$111.24M | -$96.71M | -$47.26M | -$33.19M | -$10.04M | $0 |
| EBITDA Margin | - | - | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 |
| Assets | |||||||||
| Current Assets | |||||||||
| Cash and Cash Equivalents | $325.86M | $313.63M | $437.08M | $180.8M | $233.89M | $110.19M | $22.71M | $6.02M | $5.36M |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $325.86M | $313.63M | $437.08M | $180.8M | $233.89M | $110.19M | $22.71M | $6.02M | $5.36M |
| Accounts Receivable | $5.08M | $3.29M | $1.16M | $427K | $782K | $636K | $236K | $0 | $1K |
| Inventory | $0 | $0 | $0 | $4.52M | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $0 | $0 | $694K | $651K | $6K | $1.35M | $0 | $0 | $0 |
| Total Current Assets | $334.23M | $323.34M | $444.48M | $186.4M | $236.36M | $112.78M | $23M | $6.07M | $5.36M |
| Long-Term Assets | |||||||||
| Property, Plant & Equipment Net | $1.56M | $1.65M | $509K | $700K | $393K | $54K | $14K | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $991K | $530K | $433K | $290K | $192K | $111K | $0 | $0 | $0 |
| Other Long-Term Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Long-Term Assets | $2.55M | $2.18M | $942K | $990K | $585K | $165K | $14K | $0 | $0 |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $336.79M | $325.52M | $445.42M | $187.39M | $236.95M | $112.95M | $23.01M | $6.07M | $5.36M |
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts Payable | $5.71M | $5.1M | $3.25M | $6.68M | $2.37M | $733K | $578K | $275K | $68K |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $1.05M | $672K | $481K | $1.3M | $549K | $213K | $9K | $700 | $1K |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $12.77M | $8.74M | $480K | $515K | $1.63M | $978K | $0 | $0 | $0 |
| Total Current Liabilities | $33.07M | $25.67M | $16.31M | $20.36M | $7.81M | $5.94M | $2.15M | $538K | $155K |
| Long-Term Liabilities | |||||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $0 | $0 | -$1 | $0 | $0 | $0 | $0 |
| Total Long-Term Liabilities | $644K | $714K | $49K | $279K | $168K | $0 | $0 | $275K | $68K |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$275K | -$68K |
| Total Liabilities | $33.72M | $26.38M | $16.36M | $20.64M | $7.97M | $5.94M | $2.15M | $538K | $155K |
| Stockholders' Equity | |||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $59K | $0 |
| Common Stock | $8.74M | $7.29M | $7.01M | $4.53M | $4.44M | $263K | $146K | $113K | $113K |
| Retained Earnings | -$647.52M | -$449.4M | -$297.08M | -$183.43M | -$97.83M | -$49.67M | -$20.64M | -$11.67M | -$6.85M |
| Comprehensive Income & Other | $56.41M | $44.52M | $31.15M | $22.58M | $10.95M | $2.21M | $438K | $308K | $196K |
| Other Stockholders' Equity | $941.85M | $741.25M | $719.13M | $345.65M | $322.36M | $156.42M | $41.36M | $17.09M | $11.94M |
| Total Equity | $303.07M | $299.14M | $429.06M | $166.75M | $228.97M | $107.01M | $20.86M | $5.53M | $5.2M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $336.79M | $325.52M | $445.42M | $187.39M | $236.95M | $112.95M | $23.01M | $6.07M | $5.36M |
| Supplementary Data | |||||||||
| Total Debt | $868K | $962K | $267K | $488K | $280K | $0 | $0 | $0 | $0 |
| Net Debt | -$325M | -$312.67M | -$436.82M | -$180.32M | -$233.61M | -$110.19M | -$22.71M | -$6.02M | -$5.36M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Operating Activities | ||||||||
| Net Income | -$194.07M | -$147.91M | -$111.53M | -$84.52M | -$47.66M | -$29.12M | -$8.97M | -$4.82M |
| Depreciation & Amortization | $467K | $301K | $288K | $171K | $86K | $8K | $613 | $4.82M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $21.28M | $18.11M | $11.91M | $12.68M | $9.16M | $1.77M | $130K | $113K |
| Changes in Working Capital: | ||||||||
| Accounts Receivable | -$370K | -$38K | -$46K | $355K | -$146K | -$401K | -$233K | -$55K |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $4K | $0 |
| Accounts Payable | $0 | $0 | $0 | $0 | $0 | $0 | $306K | $211K |
| Other Working Capital | $8.89M | $6.62M | -$6.5M | $9M | $1.91M | $2.16M | $1.31M | $181K |
| Total Working Capital Change | $8.52M | $6.58M | -$6.55M | $9.36M | $1.76M | $1.76M | $1.38M | $326K |
| Other Non-Cash Items | $10.66M | -$11.29M | $1.92M | -$12.72M | -$13.17M | $1.57M | -$4K | -$4.82M |
| Net Cash from Operating | -$153.14M | -$134.21M | -$103.95M | -$75.03M | -$49.83M | -$24.02M | -$7.46M | -$4.38M |
| Investing Activities | ||||||||
| Capital Expenditures | -$184K | -$601K | -$101K | -$139K | -$145K | -$48K | -$15K | $0 |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | -$184K | -$601K | -$101K | -$139K | -$145K | -$48K | -$15K | $0 |
| Financing Activities | ||||||||
| Debt Repaid | $245K | $178K | $246K | $134K | - | - | - | - |
| Common Stock Issuance | $191.87M | $2.51M | $383.1M | $10.74M | $175.21M | $114.53M | $25.1M | $5.04M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$12.19M | $661K | -$19.33M | -$938K | -$14.7M | -$1.47M | -$934K | $0 |
| Net Cash from Financing | $179.43M | $2.99M | $363.53M | $9.66M | $160.51M | $113.06M | $24.17M | $5.04M |
| Forex Effect | -$13.87M | $8.37M | -$3.19M | $12.42M | $13.16M | -$1.51M | $0 | $0 |
| Net Change in Cash | $12.23M | -$123.45M | $256.28M | -$53.08M | $123.7M | $87.48M | $16.69M | $659K |
| Supplementary Data | ||||||||
| Operating Cash Flow | -$153.14M | -$134.21M | -$103.95M | -$75.03M | -$49.83M | -$24.02M | -$7.46M | -$4.38M |
| Capital Expenditure | -$184K | -$601K | -$101K | -$139K | -$145K | -$48K | -$15K | $0 |
| Free Cash Flow | -$153.32M | -$134.81M | -$104.05M | -$75.17M | -$49.97M | -$24.07M | -$7.47M | -$4.38M |
| Cash at Beginning | $313.63M | $437.08M | $180.8M | $233.89M | $110.19M | $22.71M | $6.02M | $5.36M |
| Cash at End | $325.86M | $313.63M | $437.08M | $180.8M | $233.89M | $110.19M | $22.71M | $6.02M |